NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Genocea Biosciences Stock (NASDAQ:GNCA) Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2,100 shsAverage Volume83,499 shsMarket Capitalization$6 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genocea Biosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel T cell-directed therapies and vaccines for oncology and infectious diseases. Headquartered in Cambridge, Massachusetts, Genocea aims to leverage the body’s natural immune response by identifying the precise antigens that drive protective T cell activity. The company’s proprietary ATLAS platform enables comprehensive mapping of antigen-specific CD4+ and CD8+ T cell responses. By screening patient-derived samples against a broad library of peptides, ATLAS identifies the targets most likely to elicit potent, disease-relevant immune responses. Genocea is applying this technology across multiple programs, including investigational cancer vaccines and infectious disease initiatives, and is pursuing strategic collaborations with pharmaceutical and biotechnology partners to advance its pipeline. Founded in 2011 as a spin-out from academic research, Genocea has built a multidisciplinary team of immunologists, molecular biologists and clinical development experts. While the company’s early work established proof of concept for its epitope identification approach, ongoing efforts are focused on translating ATLAS discoveries into off-the-shelf and personalized immunotherapies. Genocea serves a global market through its Cambridge laboratories and collaborative network, with the goal of accelerating next-generation treatments that harness T cell immunity.AI Generated. May Contain Errors. Read More Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNCA Stock News HeadlinesGenocea Biosciences Inc.April 20, 2026 | barrons.comGenocea Biosciences Inc GNCAQJanuary 5, 2024 | morningstar.comMA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 20 at 1:00 AM | Porter & Company (Ad)GNCAQ Genocea Biosciences, Inc.January 26, 2023 | seekingalpha.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 31, 2022 | thestreet.comGenocea Biosciences, Inc. (GNCA)August 9, 2022 | uk.finance.yahoo.comGRPN, GNCA and LAB among mid-day moversMay 27, 2022 | seekingalpha.comGenocea Biosciences to shut downMay 25, 2022 | finance.yahoo.comSee More Headlines GNCA Stock Analysis - Frequently Asked Questions How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Chipotle Mexican Grill (CMG), BlackRock (BLK), Micron Technology (MU). Company Calendar Last Earnings10/27/2021Today8/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GNCA CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year Founded2006Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.20 million Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / BookN/AMiscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$6 thousand OptionableNot Optionable Beta1.61 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:GNCA) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThis tiny launch company operates next to SpaceX and Blue OriginA small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredThis could help save your retirementMurray Stahl is a Wall Street money manager who put more than half of his $9 billion firm into a single stock ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
